Valuation: Gritstone bio, Inc.

Capitalization 18.46L 17.94L 16.83L 15.09L 26.58L 16Cr 29.69L 2.06Cr 76.48L 6.54Cr 69.28L 67.82L 29Cr P/E ratio 2022
-2.61x
P/E ratio 2023 -1.7x
Enterprise value 2.73Cr 2.66Cr 2.49Cr 2.24Cr 3.94Cr 236.81Cr 4.4Cr 30Cr 11Cr 97Cr 10Cr 10Cr 424.68Cr EV / Sales 2022
7.62x
EV / Sales 2023 13.5x
Free-Float
98.27%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Gritstone bio, Inc.

1 day-50.00%
1 week-98.65%
Current month-99.20%
1 month-99.29%
3 months-99.83%
6 months-99.99%
Current year-99.20%
More quotes
1 week
0.00
Extreme 0
0.01
1 month
0.00
Extreme 0
0.02
Current year
0.00
Extreme 0
0.01
1 year
0.00
Extreme 0
3.14
3 years
0.00
Extreme 0
6.19
5 years
0.00
Extreme 0
35.20
10 years
0.00
Extreme 0
35.20
More quotes
Director TitleAgeSince
Chief Executive Officer 45 31/12/2024
Investor Relations Contact - 01/12/2021
Human Resources Officer - -
Manager TitleAgeSince
Director/Board Member 58 01/08/2015
Chairman 70 01/05/2020
Director/Board Member 51 01/06/2021
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-50.00%-98.65%-100.00%-100.00%14.77T
-1.72%+1.18%-4.69%+78.14%11TCr
-1.45%-5.50%-26.04%+12.68%7.46TCr
-0.19%-0.22%+83.67%+156.91%3.98TCr
-0.80%-7.69%+13.25%-42.47%2.7TCr
+1.79%+15.44%+18.52%-13.95%2.19TCr
+0.47%+1.75%-27.02%-53.04%2.09TCr
-0.45%+2.31%+7.01%+81.11%1.44TCr
-0.05%-3.35%+425.72%+661.09%1.34TCr
+2.69%-5.01%-25.11%-33.44%1.34TCr
Average -4.97%-9.98%+36.53%+74.70% 3.33TCr
Weighted average by Cap. -0.73%-0.39%+19.72%+67.96%
See all sector performances

Financials

2022 2023
Net sales 1.99Cr 1.94Cr 1.82Cr 1.63Cr 2.87Cr 172.71Cr 3.21Cr 22Cr 8.26Cr 71Cr 7.48Cr 7.33Cr 309.73Cr 1.63Cr 1.59Cr 1.49Cr 1.34Cr 2.35Cr 141.53Cr 2.63Cr 18Cr 6.77Cr 58Cr 6.13Cr 6Cr 253.81Cr
Net income -12Cr -12Cr -11Cr -9.78Cr -17Cr -1.04TCr -19Cr -133.37Cr -50Cr -424.12Cr -45Cr -44Cr -1.86TCr -14Cr -13Cr -13Cr -11Cr -20Cr -1.2TCr -22Cr -154.33Cr -57Cr -490.75Cr -52Cr -51Cr -2.15TCr
Net Debt -14Cr -13Cr -12Cr -11Cr -20Cr -1.17TCr -22Cr -151.11Cr -56Cr -480.51Cr -51Cr -50Cr -2.11TCr 2.55Cr 2.48Cr 2.32Cr 2.08Cr 3.67Cr 220.82Cr 4.1Cr 28Cr 11Cr 90Cr 9.57Cr 9.37Cr 396.01Cr
More financial data * Estimated data
Logo Gritstone bio, Inc.
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Employees
231
More about the company
Date Price Change Volume
16/25/16 0.000100 $ -50.00% 373,139
15/25/15 0.000200 $ -96.43% 325,600
14/25/14 0.005600 $ -13.31% 2,053,690
13/25/13 0.006460 $ -1.37% 1,234,554
10/25/10 0.006550 $ -11.49% 954,319

Delayed Quote OTC Markets, January 17, 2025 at 02:20 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.000100
Average target price
-
Consensus

Quarterly revenue - Rate of surprise